If this is your first visit, be sure to
check out the FAQ by clicking the
link above. You may have to register
before you can post: click the register link above to proceed. To start viewing messages,
select the forum that you want to visit from the selection below.
Dorian80, mitico.
Però sollevo un dubbio: siamo sicuri che questi acidi grassi hanno il potere di influenzare la sensibilita' insulinica e la secrezione di GH? Hmmm, ci credo poco (anzi niente).
Personal Fitness Trainer certificato I.S.S.A. - CFT 1
Dorian80, mitico.
Però sollevo un dubbio: siamo sicuri che questi acidi grassi hanno il potere di influenzare la sensibilita' insulinica e la secrezione di GH? Hmmm, ci credo poco (anzi niente).
Il potere lo hanno...
Ovvio che in una dose minimale e che nn fa' la DIFFERENZA...
Effects of omega-3 polyunsaturated fatty acids on depression.
Severus WE.
Depression is characterised by depressed mood or/ and the loss of interest or pleasure in nearly all activities for a substantial period of time, causing significant distress. Depression is a potentially life-threatening disease. It is a major risk factor for suicide as well as coronary artery disease (CAD) and sudden cardiac death (SCD). It also may be associated with impaired endothelial dysfunction and decreased heart rate variability (HRV). Both conditions seem to persist in patients with depression despite successful antidepressant treatment. During the last few years epidemiological studies as well as clinical trials have suggested a significant role of omega-3 fatty acids in the pathogenesis of depression. As omega-3 fatty acids have been demonstrated to also beneficially influence many of the conditions depression is a risk factor for (CAD, SCD) or may be associated with (decreased HRV, endothelial dysfunction), they may well represent a major advance in the treatment of depression. However more large randomized clinical trials are clearly needed to substantiate that claim.
Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A.
BACKGROUND: People with type 2 diabetes mellitus are at increased risk from cardiovascular disease. Dietary omega-3 polyunsaturated fatty acids (PUFAs) are known to reduce triglyceride levels, but their impact on cholesterol levels, glycemic control and vascular outcomes are not well known. OBJECTIVES: To determine the effects of omega-3 PUFA supplementation on cardiovascular outcomes, cholesterol levels and glycemic control in people with type 2 diabetes mellitus. SEARCH STRATEGY: We carried out a comprehensive search of The Cochrane Library, MEDLINE, EMBASE, bibliographies of relevant papers and contacted experts for identifying additional trials. SELECTION CRITERIA: All randomised controlled trials were included where omega-3 PUFA supplementation or dietary intake was randomly allocated and unconfounded in people with type 2 diabetes. Authors of large trials were contacted for missing information. DATA COLLECTION AND ANALYSIS: Trials were assessed for inclusion. Authors were contacted for missing information. Data was extracted and quality assessed independently in duplicate. Fixed-effect meta-analysis was carried out. MAIN RESULTS: Twenty three randomised controlled trials (1075 participants) were included with a mean treatment duration of 8.9 weeks. The mean dose of omega-3 PUFA used in the trials was 3.5 g/d. No trials with vascular events or mortality endpoints were identified. Among those taking omega-3 PUFA triglyceride levels were significantly lowered by 0.45 mmol/L (95% confidence interval (CI) -0.58 to -0.32, P < 0.00001) and VLDL cholesterol lowered by -0.07 mmol/L (95% CI -0.13 to 0.00, P = 0.04). LDL cholesterol levels were raised by 0.11 mmol/L (95% CI 0.00 to 0.22, P = 0.05). No significant change in or total or HDL cholesterol, HbA1c, fasting glucose, fasting insulin or body weight was observed. The increase in VLDL remained significant only in trials of longer duration and in hypertriglyceridemic patients. The elevation in LDL cholesterol was non-significant in subgroup analyses. No adverse effects of the intervention were reported. AUTHORS' CONCLUSIONS: Omega-3 PUFA supplementation in type 2 diabetes lowers triglycerides and VLDL cholesterol, but may raise LDL cholesterol (although results were non-significant in subgroups) and has no statistically significant effect on glycemic control or fasting insulin. Trials with vascular events or mortality defined endpoints are needed.
Prevention of cardiovascular diseases and highly concentrated n-3 polyunsaturated fatty acids (PUFAs).
Weber HS, Selimi D, Huber G.
30 years ago the observation of a lower incidence of cardiovascular diseases in Inuits (Eskimos) was related to the higher fish consumption when compared to the residual Danish population. Clinical studies confirmed this finding. It was explained by the higher content of polyunsaturated fatty acids (PUFA) in fish, especially of omega-3 PUFAs. Experimental studies in cell cultures and also in animals with and without infarction models verified the anti-arrhythmic effect of omega-3 PUFAs among other possible contributing factors when compared to other fatty acids. In clinical studies a significant reduction (ca. 40%) of sudden cardiac deaths (SCD) could be found in patients after an acute myocardial infarction, if they were treated with at least 1 g omega-3 PUFAs daily, either by consumption of fish twice weekly or of a highly purified preparation omega-3 PUFAs in capsules. These findings led to recommendations of the American Heart Association and the European Society of Cardiology to a higher fish consumption and/or the daily intake of 1 g omega-3 PUFAs for primary and especially for secondary prevention of cardiovascular diseases. The much fewer side-effects, and the standardised dosage on one hand and the negative effect of the sometimes higher mercury content of fish make the intake of omega-3 PUFAs as capsules the better choice.
Non sembri che migliori la sensibilità all'insulina!
Effects of omega-3 polyunsaturated fatty acids on depression.
Severus WE.
Depression is characterised by depressed mood or/ and the loss of interest or pleasure in nearly all activities for a substantial period of time, causing significant distress. Depression is a potentially life-threatening disease. It is a major risk factor for suicide as well as coronary artery disease (CAD) and sudden cardiac death (SCD). It also may be associated with impaired endothelial dysfunction and decreased heart rate variability (HRV). Both conditions seem to persist in patients with depression despite successful antidepressant treatment. During the last few years epidemiological studies as well as clinical trials have suggested a significant role of omega-3 fatty acids in the pathogenesis of depression. As omega-3 fatty acids have been demonstrated to also beneficially influence many of the conditions depression is a risk factor for (CAD, SCD) or may be associated with (decreased HRV, endothelial dysfunction), they may well represent a major advance in the treatment of depression. However more large randomized clinical trials are clearly needed to substantiate that claim.
Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A.
BACKGROUND: People with type 2 diabetes mellitus are at increased risk from cardiovascular disease. Dietary omega-3 polyunsaturated fatty acids (PUFAs) are known to reduce triglyceride levels, but their impact on cholesterol levels, glycemic control and vascular outcomes are not well known. OBJECTIVES: To determine the effects of omega-3 PUFA supplementation on cardiovascular outcomes, cholesterol levels and glycemic control in people with type 2 diabetes mellitus. SEARCH STRATEGY: We carried out a comprehensive search of The Cochrane Library, MEDLINE, EMBASE, bibliographies of relevant papers and contacted experts for identifying additional trials. SELECTION CRITERIA: All randomised controlled trials were included where omega-3 PUFA supplementation or dietary intake was randomly allocated and unconfounded in people with type 2 diabetes. Authors of large trials were contacted for missing information. DATA COLLECTION AND ANALYSIS: Trials were assessed for inclusion. Authors were contacted for missing information. Data was extracted and quality assessed independently in duplicate. Fixed-effect meta-analysis was carried out. MAIN RESULTS: Twenty three randomised controlled trials (1075 participants) were included with a mean treatment duration of 8.9 weeks. The mean dose of omega-3 PUFA used in the trials was 3.5 g/d. No trials with vascular events or mortality endpoints were identified. Among those taking omega-3 PUFA triglyceride levels were significantly lowered by 0.45 mmol/L (95% confidence interval (CI) -0.58 to -0.32, P < 0.00001) and VLDL cholesterol lowered by -0.07 mmol/L (95% CI -0.13 to 0.00, P = 0.04). LDL cholesterol levels were raised by 0.11 mmol/L (95% CI 0.00 to 0.22, P = 0.05). No significant change in or total or HDL cholesterol, HbA1c, fasting glucose, fasting insulin or body weight was observed. The increase in VLDL remained significant only in trials of longer duration and in hypertriglyceridemic patients. The elevation in LDL cholesterol was non-significant in subgroup analyses. No adverse effects of the intervention were reported. AUTHORS' CONCLUSIONS: Omega-3 PUFA supplementation in type 2 diabetes lowers triglycerides and VLDL cholesterol, but may raise LDL cholesterol (although results were non-significant in subgroups) and has no statistically significant effect on glycemic control or fasting insulin. Trials with vascular events or mortality defined endpoints are needed.
Prevention of cardiovascular diseases and highly concentrated n-3 polyunsaturated fatty acids (PUFAs).
Weber HS, Selimi D, Huber G.
30 years ago the observation of a lower incidence of cardiovascular diseases in Inuits (Eskimos) was related to the higher fish consumption when compared to the residual Danish population. Clinical studies confirmed this finding. It was explained by the higher content of polyunsaturated fatty acids (PUFA) in fish, especially of omega-3 PUFAs. Experimental studies in cell cultures and also in animals with and without infarction models verified the anti-arrhythmic effect of omega-3 PUFAs among other possible contributing factors when compared to other fatty acids. In clinical studies a significant reduction (ca. 40%) of sudden cardiac deaths (SCD) could be found in patients after an acute myocardial infarction, if they were treated with at least 1 g omega-3 PUFAs daily, either by consumption of fish twice weekly or of a highly purified preparation omega-3 PUFAs in capsules. These findings led to recommendations of the American Heart Association and the European Society of Cardiology to a higher fish consumption and/or the daily intake of 1 g omega-3 PUFAs for primary and especially for secondary prevention of cardiovascular diseases. The much fewer side-effects, and the standardised dosage on one hand and the negative effect of the sometimes higher mercury content of fish make the intake of omega-3 PUFAs as capsules the better choice.
Non sembri che migliori la sensibilità all'insulina!
non basta postare gli studi ma bisogna anche saperli leggere.
Ti sembrano condotti su soggetti sani?...dubito che lo stesso studio affrontato su sogg malati e sani, pur mantenendo le stesse modalità di esecuzione, dia lo stesso risultato finale.
Inoltre se ricerchi su Pubmed troverai studi (condotti su persone sane)che provano la capacità degli acidi grassi polynsaturi di migliorare la sensibilità insulinica.
"è una vergogna per un uomo invecchiare senza vedere la bellezza e la forza di cui il suo corpo è capace" (Socrate)
Bellero questo non è uno studio ma una revisione sistematica svolta con la meta analisi. Quindi non è un solo studio ma una serie di studi condotti in un certo periodo di tempo.
Mi fido molto di più di una revisione sistematica piuttosto che di uno studietto singolo svolto alcune volte anche in malo modo.
Inoltre se la sostanza X migliore la sensibilità nei sani nn vedo perchè non potrebbe farlo anche nei malati.
Se posti qualche revisione sistematica su soggetti sani che hanno assunto omega - 3 e hanno migliorato la sensibilità all'insulina, sarò felice di leggerla.
Bellero questo non è uno studio ma una revisione sistematica svolta con la meta analisi. Quindi non è un solo studio ma una serie di studi condotti in un certo periodo di tempo.
Mi fido molto di più di una revisione sistematica piuttosto che di uno studietto singolo svolto alcune volte anche in malo modo.
Inoltre se la sostanza X migliore la sensibilità nei sani nn vedo perchè non potrebbe farlo anche nei malati.
Se posti qualche revisione sistematica su soggetti sani che hanno assunto omega - 3 e hanno migliorato la sensibilità all'insulina, sarò felice di leggerla.
per me hanno valenza entrambi studi, e revisioni sistemiche se di fondo ci sono le giuste modalità di condotta. Però rimane cmq l'incongruenza di base perchè possa essere preso come rifermento: i sogg presi in esame. Quello che tu ipotizzi potrebbe anche essere vero ma con i se non si va avanti e dato che non c'è alcuno studio che provi la stessa identica cosa su soggetti sani nessuno può confermare ciò che dici.
Su pubmed basta fare una ricerca perchè escano pagine di studi in merito agli omega-3, ma eccetto in questo che hai riportato, condotto su diabetici di tipoII il che significa già con una "deficenza" funzionale insulinica cronica, in nessun altro si giunge a quelle osservazioni (fra l'altro nel caso dei diabetici sono correlati anche ad un innalzamento dell'LDL, altro "comportamento" insolito)
"è una vergogna per un uomo invecchiare senza vedere la bellezza e la forza di cui il suo corpo è capace" (Socrate)
Assumendo una sola capsula di un medicinale a base di esteri etilici di acidi grassi poliinsaturi da 1000 mg al giorno e' giusta come quantità'..?
Ogni capsula contiene: Esteri etilici di acidi grassi poliinsaturi con un contenuto in EPA E DHA NON INFERIORE ALL'85 % ed in rapporto fra loro di 0,9 - 1,5 1000 mg.
Solitamente assumo la capsula nello spuntino mattutino con un frutto.
Considerando che mi alleno la sera, non credo influisca negativamente.
In ogni caso mi risulta un po' pesante, nella mezza ora successiva all'assunzione, mi sembra di aver ingoiato un pesce intero.
Grazie..!
Gli acidi grassi omega-3,presenti negli oli di pesce(soprattuto EPA e DHA)e nell'olio di semi di lino(attenzione qui alla conversione,specie se assunti in concomitanza a xantine-caffeina e negli over 30),sono utili in moltissime situazioni.
vuol dire che negli over 30(maggiormente)la conversione di olio di lino-acidi grassi o3 e' molto difficile e instabile specie se assunto nelle ore in cui si e' assunta caffeina ad esempio...
We process personal data about users of our site, through the use of cookies and other technologies, to deliver our services, personalize advertising, and to analyze site activity. We may share certain information about our users with our advertising and analytics partners. For additional details, refer to our Privacy Policy.
By clicking "I AGREE" below, you agree to our Privacy Policy and our personal data processing and cookie practices as described therein. You also acknowledge that this forum may be hosted outside your country and you consent to the collection, storage, and processing of your data in the country where this forum is hosted.
Commenta